Multimodal prehabilitation enhances innate antitumor immunity via NK cell recruitment

Lixuan Feng,Ben Gordon,Xin Su,Ariane Brassard,Iqraa Dhoparee-Doomah,Sabrina Leo,Rashami Awasthi,France Bourdeau,Betty Giannias,Heather Gill,Enrico Minnella,Lorenzo Ferri,Sara Najmeh,Jonathan Spicer,Francesco Carli,Jonathan Cools-Lartigue

DOI: https://doi.org/10.1101/2024.08.05.24311508

2024-08-06

Abstract:BACKGROUND: While the clinical benefits of multimodal prehabilitation in cancer patients are well defined, the underlying immune modulations have not been studied. The objective of this study was to examine how prehabilitation can alter lung cancer immunity. METHODS: Newly diagnosed lung cancer patients were referred to the prehabilitation clinic for preoperative personalized multimodal intervention (exercise training, nutritional optimization, and anxiety reduction) and blood samples were collected at baseline and surgery. Tumor samples were collected at surgery and compared to matched control samples from patients who did not receive prehabilitation. An animal model was used to study prehabilitation and tumor growth kinetics. RESULTS: Twenty-eight lung cancer patients who underwent multimodal prehabilitation were included (McGill University Health Centre Research Ethics Board #2023-9005). After prehabilitation, patient-isolated peripheral blood mononuclear cells (PBMCs) showed significantly increased cytotoxicity against cancer cells (p < 0.0001) and significantly increased circulating natural killer (NK) cells in cohort (p = 0.0290) and paired analyses (p = 0.0312). Compared to matched controls, patients who received prehabilitation had significantly more intra-tumor NK cells (p = 0.0172). In vivo, we observed a significant increase in circulating NK cells (p = 0.0364) and slower tumor growth (p = 0.0396) with prehabilitation. When NK cells were depleted in prehabilitated mice, we observed a decrease in the protective effects of prehabilitation (p = 0.0314) and overall, we observed a significant correlation between circulating NK cells and reduced tumor volume (p = 0.0203, r = -0.5143). CONCLUSIONS: Multimodal prehabilitation may play a role in antitumor immunity by increasing peripheral and tumour-infiltrating NK cells leading to a reduced cancer burden. Future studies on the protective effect of prehabilitation on postoperative immunity should be conducted.

Oncology

What problem does this paper attempt to address?

The problem this paper attempts to address is whether multimodal prehabilitation can enhance the anti-tumor immune response in lung cancer patients by increasing the recruitment of natural killer (NK) cells.

Specifically, the researchers aim to explore this issue through the following points:

1. **Clinical Background**: Although the clinical benefits of multimodal prehabilitation in cancer patients are well-established, its impact on the immune system has not been fully studied. Therefore, this study aims to investigate how prehabilitation alters the immune status of lung cancer patients.

2. **Research Methods**:
- **Patient Samples**: Newly diagnosed lung cancer patients were referred to a prehabilitation clinic for preoperative personalized multimodal interventions (including exercise training, nutritional optimization, and anxiety reduction), and blood samples were collected at baseline and at the time of surgery.
- **Tumor Samples**: Tumor samples were collected at the time of surgery and compared with matched control group samples that did not receive prehabilitation.
- **Animal Models**: Animal models were used to study the impact of prehabilitation on tumor growth dynamics.

3. **Research Results**:
- **Enhanced Cytotoxicity**: After prehabilitation, the cytotoxicity of patients' peripheral blood mononuclear cells (PBMCs) against cancer cells significantly increased (p < 0.0001).
- **Increased NK Cells**: The number of circulating NK cells in patients who received prehabilitation significantly increased (cohort analysis p = 0.0290, paired analysis p = 0.0312).
- **Increased Tumor-Infiltrating NK Cells**: Compared to the matched control group, the number of NK cells within the tumors of patients who received prehabilitation significantly increased (p = 0.0172).
- **Animal Experiments**: In animal experiments, a significant increase in circulating NK cells was observed after prehabilitation (p = 0.0364), and tumor growth slowed down (p = 0.0396). When NK cells were depleted in prehabilitated mice, the protective effect of prehabilitation was reduced (p = 0.0314).

4. **Conclusion**: Multimodal prehabilitation may enhance the anti-tumor immune response by increasing the number of peripheral and tumor-infiltrating NK cells, thereby reducing the cancer burden. Further research is needed to investigate the impact of prehabilitation on postoperative immune protection.

In summary, this study aims to explore whether multimodal prehabilitation can enhance the anti-tumor immune response in lung cancer patients by increasing the recruitment of NK cells.